ARCTURUS THERAPEUTICS HLDGS's ticker is ARCT and the CUSIP is 03969T109. A total of 115 filers reported holding ARCTURUS THERAPEUTICS HLDGS in Q4 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $402 | -27.3% | 15,722 | -18.4% | 0.00% | – |
| Q2 2023 | $553 | +15.9% | 19,257 | -3.1% | 0.00% | – |
| Q1 2023 | $477 | +42.4% | 19,874 | +0.5% | 0.00% | – |
| Q4 2022 | $335 | -99.9% | 19,769 | +8.3% | 0.00% | – |
| Q3 2022 | $271,000 | +3.0% | 18,247 | +9.1% | 0.00% | – |
| Q2 2022 | $263,000 | -40.2% | 16,732 | +2.5% | 0.00% | – |
| Q1 2022 | $440,000 | -21.0% | 16,322 | +8.5% | 0.00% | – |
| Q4 2021 | $557,000 | -20.9% | 15,039 | +2.0% | 0.00% | – |
| Q3 2021 | $704,000 | -84.4% | 14,741 | -89.0% | 0.00% | – |
| Q2 2021 | $4,526,000 | -40.1% | 133,741 | -26.9% | 0.00% | -100.0% |
| Q1 2021 | $7,561,000 | -87.7% | 183,069 | -87.1% | 0.00% | -83.3% |
| Q4 2020 | $61,694,000 | +104.5% | 1,422,179 | +102.2% | 0.01% | +100.0% |
| Q3 2020 | $30,175,000 | +24.7% | 703,386 | +35.8% | 0.00% | 0.0% |
| Q2 2020 | $24,204,000 | – | 517,837 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DFPG INVESTMENTS, LLC | 456,390 | $5,541,000 | 3.62% |
| DAFNA Capital Management LLC | 173,914 | $1,890,000 | 0.65% |
| One68 Global Capital, LLC | 19,861 | $216,000 | 0.47% |
| Diametric Capital, LP | 51,982 | $565,000 | 0.41% |
| ARK Investment Management | 1,383,756 | $15,041,000 | 0.38% |
| EAM Investors, LLC | 52,833 | $574,000 | 0.13% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 31,404 | $341,000 | 0.05% |
| Nikko Asset Management Americas, Inc. | 280,548 | $3,050,000 | 0.05% |
| MGO ONE SEVEN LLC | 14,900 | $161,000 | 0.04% |
| Qube Research & Technologies Ltd | 67,702 | $736,000 | 0.02% |